1. Home
  2. BNGO vs BCDA Comparison

BNGO vs BCDA Comparison

Compare BNGO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.28

Market Cap

12.5M

Sector

Industrials

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.22

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
BCDA
Founded
2003
N/A
Country
United States
United States
Employees
N/A
21
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
12.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
BCDA
Price
$1.28
$1.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$25.00
AVG Volume (30 Days)
288.8K
53.4K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
94.50
N/A
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
$14.99
N/A
Revenue Next Year
$34.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$1.00
52 Week High
$5.50
$3.20

Technical Indicators

Market Signals
Indicator
BNGO
BCDA
Relative Strength Index (RSI) 55.48 51.76
Support Level $1.09 $1.12
Resistance Level $1.64 $1.31
Average True Range (ATR) 0.05 0.06
MACD 0.01 0.01
Stochastic Oscillator 66.68 67.65

Price Performance

Historical Comparison
BNGO
BCDA

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: